Tumor microenvironment

SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer

Retrieved on: 
Tuesday, February 1, 2022

NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced today the completion of enrollment in the Phase 1/2 clinical trial of the Company’s lead asset, galinpepimut-S (GPS), in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in second or third line Wilms Tumor-1 (WT1)(+) relapsed or refractory metastatic ovarian cancer. The endpoints of the study include safety, overall response rate, progression-free survival, overall survival and immune response correlates. The clinical trial is being conducted under a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J. USA (known as MSD outside of the United States and Canada).

Key Points: 
  • Data from 15 patients will be examined by mid-2022, with final data analysis for all evaluable patients expected by the end of 2022.
  • SELLAS and Merck will jointly perform applicable analyses of the study, including survival, immune-biological and any other analyses of interest, to assess the safety and efficacy profile of the combination of GPS and pembrolizumab in this difficult-to-treat metastatic ovarian cancer indication.
  • Completion of enrollment is an important milestone as we work diligently to evaluate a much-needed therapeutic treatment option for second or third line relapsed or refractory metastatic ovarian cancer patients, said Angelos Stergiou, MD, ScD.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications.

Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors

Retrieved on: 
Monday, January 31, 2022

Dr. Stampacchia joined the Replimune Board in 2015, concurrent with Omega co-leading Replimunes seed financing.

Key Points: 
  • Dr. Stampacchia joined the Replimune Board in 2015, concurrent with Omega co-leading Replimunes seed financing.
  • Dr. Stampacchia has resigned to focus his efforts on his growing commitments at Omega and its many portfolio companies.
  • I would personally like to thank Otello for his numerous contributions to Replimunes Board of Directors as we have grown from concept to a late-stage development company said Philip Astley-Sparke, Chief Executive Officer of Replimune.
  • We are grateful for his service and I am joined by other directors and members of Replimunes executive team in wishing him well.

Global Active Pharmaceutical Ingredient (Captive API & Merchant API) Markets Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022

The "Active Pharmaceutical Ingredient (API) Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Active Pharmaceutical Ingredient (API) Market" report has been added to ResearchAndMarkets.com's offering.
  • The surge in corona cases worldwide has played an essential role in active pharmaceutical ingredient manufacturers' development over the forecast period.
  • The European regional active pharmaceutical ingredient market is anticipated to account for a second principal market share through the forecast period.
  • The Asia Pacific active pharmaceutical ingredient market is assessed to be the fastest encouraging region in the worldwide active pharmaceutical ingredient market because of the commonness of quickly emerging markets are developing as core hubs for outsourcing drug manufacturing.

AXL Kinase Inhibitor Pipeline Market Report 2022: Insights on 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022

This "AXL Kinase Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape.

Key Points: 
  • This "AXL Kinase Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape.
  • AXL receptor tyrosine Kinase is a member of the tyrosine-protein Kinase receptor Tyro3, Axl and proto-oncogene tyrosine-protein Kinase Mer family of receptor tyrosine Kinases.
  • This segment of the report provides insights about the different AXL Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • The companies which have their AXL Kinase Inhibitor drug candidates in the most advanced stage, i.e.

Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement

Retrieved on: 
Friday, January 28, 2022

The shares of Series D preferred stock are convertible into shares of the Companys common stock, upon the occurrence of certain events, at a conversion price of $0.25 per share of common stock.

Key Points: 
  • The shares of Series D preferred stock are convertible into shares of the Companys common stock, upon the occurrence of certain events, at a conversion price of $0.25 per share of common stock.
  • The Company will be permitted to compel conversion of the Series D preferred stock after the fulfillment of certain conditions and subject to certain limitations.
  • The Company and the holders of the Series D preferred stock will also enter into a registration rights agreement to register the resale of the shares of common stock issuable upon conversion of the Series D preferred stock.
  • Total gross proceeds from the offering, before deducting thefinancial advisor's fees and other estimated offering expenses, are $4.75 million.

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

Retrieved on: 
Thursday, January 27, 2022

The dose escalation cohort will evaluate the safety and tolerability of this novel, proprietary combination in patients with advanced/metastatic solid tumors.

Key Points: 
  • The dose escalation cohort will evaluate the safety and tolerability of this novel, proprietary combination in patients with advanced/metastatic solid tumors.
  • While the oncology community has long known of the compelling preclinical rationale for this intriguing combination, safety has been a barrier to further exploration.
  • The combination is part of an open-label, global phase 1b/2 clinical trial (ADG116-1003) at multiple sites in the U.S. and Asia Pacific (APAC).
  • ADG116 has achieved the recommended dosing range as a single agent and for evaluation in combination therapy.

Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors

Retrieved on: 
Wednesday, January 26, 2022

BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced the appointment of Richard Wooster, Ph.D., to its Board of Directors.

Key Points: 
  • BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced the appointment of Richard Wooster, Ph.D., to its Board of Directors.
  • He brings novel insights and experience that will be indispensable as we continue to build our pipeline, said Mark Manfredi, Ph.D., Chief Executive Officer of Ikena.
  • We are honored to welcome him to our Board of Directors as we continue to advance our targeted oncology programs.
  • Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.

Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

Retrieved on: 
Tuesday, January 25, 2022

Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology.

Key Points: 
  • Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology.
  • Ms. Campbell will join Merus as Executive Vice President & Chief Commercial Officer in February to lead the commercial strategy for the most advanced clinical candidate, zenocutuzumab (Zeno), as well as Merus robust pipeline of multispecific product candidates in development.
  • Merus holds global rights to all four clinical candidates, apart from MCLA-129, for which Merus licensed to Betta Pharmaceuticals the exclusive right to develop and commercialize in China.
  • Merus also announced today that Incyte (Nasdaq: INCY) has elected to opt-out of its ex-U.S. development of MCLA-145, restoring full global rights to Merus.

CytoImmune Therapeutics Announces Publication Demonstrating Platelet-Derived Growth Factor D Signaling Activates Natural Killer (NK) Cells and Enhances NK Cell Survival

Retrieved on: 
Tuesday, January 25, 2022

City of Hope licensed several patent applications to CytoImmune to develop a portfolio of chimeric antigen receptor (CAR) NK cell therapies.

Key Points: 
  • City of Hope licensed several patent applications to CytoImmune to develop a portfolio of chimeric antigen receptor (CAR) NK cell therapies.
  • "We are excited to share this data on the role of PDGF-D-PDGFR signaling in NK cells' survival.
  • This foundational data supports CytoImmune's engineering approach to enhance NK cells' survival by introducing secretory IL-15 into each NK cell.
  • This collective knowledge and experience is utilized to engineer NK cells by focusing on the tumor-reactive NK cell subset.

Prokarium Expands R&D Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline

Retrieved on: 
Wednesday, January 26, 2022

This agreement will significantly expand our R&D capabilities and will further deepen our immunotherapy pipeline.

Key Points: 
  • This agreement will significantly expand our R&D capabilities and will further deepen our immunotherapy pipeline.
  • This new multi-year agreement builds on work between Prokarium and London Biofoundry that was initiated in 2020 and will further expand Prokariums operations.
  • The team from Imperials and SynbiCITEs London Biofoundry specializes in the design, engineering and functional characterisation of synthetic DNA and organisms.
  • At the London Biofoundry, we developed a cutting-edge SynBio stack and the expertise to collaborate with researchers and biotechs to advance their R&D.